Multivariable FG regression models assessing predictors of risk of HGT in different indolent lymphomas subtypes
| . | FL (n = 23 384) . | SMZL (n = 2005) . | NMZL (n = 6374) . | EMZL (n = 12 151) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | |
| Age (y) | ||||||||||||
| ≥60 vs <60 | 1.15 | 1.02-1.30 | .02 | 0.86 | 0.59-1.27 | .50 | 1.10 | 0.82-1.47 | .50 | 1.95 | 1.43-2.67 | <.001 |
| Gender | ||||||||||||
| Male vs female | 1.46 | 1.29-1.66 | <.001 | 1.13 | 0.78-1.65 | .50 | 0.97 | 0.73-1.28 | .80 | 1.11 | 0.84-1.47 | .50 |
| Ann Arbor stage | ||||||||||||
| III-IV vs I-II | 1.60 | 1.40-1.82 | <.001 | 0.84 | 0.55-1.29 | .40 | 1.25 | 0.91-1.70 | .20 | 1.23 | 0.88-1.71 | .20 |
| Management | ||||||||||||
| Observation vs treatment | 1.23 | 1.09-1.40 | .001 | 0.74 | 0.49-1.09 | .13 | 0.71 | 0.53-0.94 | .01 | 0.64 | 0.48-0.86 | .003 |
| . | FL (n = 23 384) . | SMZL (n = 2005) . | NMZL (n = 6374) . | EMZL (n = 12 151) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . | |
| Age (y) | ||||||||||||
| ≥60 vs <60 | 1.15 | 1.02-1.30 | .02 | 0.86 | 0.59-1.27 | .50 | 1.10 | 0.82-1.47 | .50 | 1.95 | 1.43-2.67 | <.001 |
| Gender | ||||||||||||
| Male vs female | 1.46 | 1.29-1.66 | <.001 | 1.13 | 0.78-1.65 | .50 | 0.97 | 0.73-1.28 | .80 | 1.11 | 0.84-1.47 | .50 |
| Ann Arbor stage | ||||||||||||
| III-IV vs I-II | 1.60 | 1.40-1.82 | <.001 | 0.84 | 0.55-1.29 | .40 | 1.25 | 0.91-1.70 | .20 | 1.23 | 0.88-1.71 | .20 |
| Management | ||||||||||||
| Observation vs treatment | 1.23 | 1.09-1.40 | .001 | 0.74 | 0.49-1.09 | .13 | 0.71 | 0.53-0.94 | .01 | 0.64 | 0.48-0.86 | .003 |
FL grade 1 to 2.